tradingkey.logo

Illumina Inc

ILMN

89.808USD

+2.877+3.31%
Market hours ETQuotes delayed by 15 min
14.28BMarket Cap
LossP/E TTM

Illumina Inc

89.808

+2.877+3.31%
More Details of Illumina Inc Company
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Company Info
Ticker SymbolILMN
Company nameIllumina Inc
IPO dateJun 28, 2000
Founded at2000
CEOMr. Jacob Thaysen, Ph.D.
Number of employees8970
Security typeOrdinary Share
Fiscal year-endJun 28
Address5200 Illumina Way
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92122
Phone18582024500
Websitehttps://www.illumina.com
Ticker SymbolILMN
IPO dateJun 28, 2000
Founded at2000
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.94K
+98.06%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
+20.59%
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
21.03K
+21.92%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
+23.09%
Ms. Patricia (Pat) Leckman
Ms. Patricia (Pat) Leckman
Chief People Officer
Chief People Officer
19.25K
+60.86%
Mr. Scott Davies
Mr. Scott Davies
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
18.93K
+58.70%
Dr. Steven (Steve) Barnard, Ph.D.
Dr. Steven (Steve) Barnard, Ph.D.
Chief Technology Officer
Chief Technology Officer
17.13K
-31.74%
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Independent Director
Independent Director
16.43K
+29.88%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Director
Independent Director
15.19K
+21.71%
Ms. Susan E. (Sue) Siegel
Ms. Susan E. (Sue) Siegel
Independent Director
Independent Director
14.46K
+35.38%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.94K
+98.06%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
+20.59%
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
21.03K
+21.92%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
+23.09%
Ms. Patricia (Pat) Leckman
Ms. Patricia (Pat) Leckman
Chief People Officer
Chief People Officer
19.25K
+60.86%
Mr. Scott Davies
Mr. Scott Davies
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
18.93K
+58.70%
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Consumables
3.15B
72.16%
Services and Other revenue
716.00M
16.38%
Instruments
501.00M
11.46%
By RegionUSD
Name
Revenue
Proportion
United States
2.29B
52.33%
Europe
1.19B
27.10%
Asia, Middle East, and Africa
438.00M
10.02%
Greater China
308.00M
7.04%
Americas
153.00M
3.50%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
3.15B
72.16%
Services and Other revenue
716.00M
16.38%
Instruments
501.00M
11.46%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital World Investors
11.94%
The Vanguard Group, Inc.
10.29%
BlackRock Institutional Trust Company, N.A.
8.85%
Capital Research Global Investors
5.46%
State Street Global Advisors (US)
3.70%
Other
59.76%
Shareholders
Shareholders
Proportion
Capital World Investors
11.94%
The Vanguard Group, Inc.
10.29%
BlackRock Institutional Trust Company, N.A.
8.85%
Capital Research Global Investors
5.46%
State Street Global Advisors (US)
3.70%
Other
59.76%
Shareholder Types
Shareholders
Proportion
Investment Advisor
52.04%
Investment Advisor/Hedge Fund
36.71%
Hedge Fund
10.36%
Pension Fund
2.57%
Research Firm
2.52%
Bank and Trust
1.81%
Sovereign Wealth Fund
1.21%
Individual Investor
0.19%
Insurance Company
0.09%
Institutional Shareholding
Updated: Mon, Jan 20
Updated: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
2030
169.86M
107.33%
-23.09M
2024Q4
2074
166.23M
104.94%
-15.71M
2024Q3
2038
151.41M
95.06%
-11.30M
2024Q2
2033
149.41M
93.80%
-18.06M
2024Q1
2096
153.02M
96.09%
-8.97M
2023Q4
2134
150.48M
94.76%
-5.28M
2023Q3
2162
152.18M
96.14%
-14.52M
2023Q2
2203
154.10M
97.47%
-5.40M
2023Q1
2219
149.37M
94.55%
-9.34M
2022Q4
2225
149.29M
94.92%
-10.46M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
18.03M
11.38%
+1.21M
+7.22%
Dec 31, 2024
The Vanguard Group, Inc.
15.74M
9.94%
-197.96K
-1.24%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
14.03M
8.86%
+262.47K
+1.91%
Dec 31, 2024
Capital Research Global Investors
8.66M
5.47%
+1.09K
+0.01%
Feb 28, 2025
State Street Global Advisors (US)
5.79M
3.66%
+185.73K
+3.31%
Dec 31, 2024
WCM Investment Management
4.13M
2.61%
+867.67K
+26.60%
Dec 31, 2024
Loomis, Sayles & Company, L.P.
4.21M
2.66%
-132.58K
-3.05%
Dec 31, 2024
Corvex Management LP
1.70M
1.07%
-580.64K
-25.46%
Dec 31, 2024
Baillie Gifford & Co.
3.02M
1.91%
-604.62K
-16.69%
Dec 31, 2024
Brown Advisory
1.91M
1.21%
+1.91M
+54.22K%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
Invesco Biotechnology & Genome ETF
4.57%
Global X Genomics & Biotechnology ETF
4%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.84%
First Trust NYSE Arca Biotechnology Index Fund
3.37%
VanEck Biotech ETF
2.86%
ARK Genomic Revolution ETF
1.8%
ROBO Global Healthcare Technology & Innovation ETF
1.78%
Alger Russell Innovation ETF
1.77%
First Trust Nasdaq AI and Robotics ETF
1.69%
Invesco Raymond James SB-1 Equity ETF
1.68%
View more
Invesco Biotechnology & Genome ETF
Proportion4.57%
Global X Genomics & Biotechnology ETF
Proportion4%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion3.84%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.37%
VanEck Biotech ETF
Proportion2.86%
ARK Genomic Revolution ETF
Proportion1.8%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.78%
Alger Russell Innovation ETF
Proportion1.77%
First Trust Nasdaq AI and Robotics ETF
Proportion1.69%
Invesco Raymond James SB-1 Equity ETF
Proportion1.68%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI